Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

doi:10.1186/s13046-020-01805-6

HFCAS OpenIR

	Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
	Ma,Liying 1,2,3; Bian,Xing 1,2,3; Lin,Wenchu 1,3
	2021-01-05
发表期刊	Journal of Experimental & Clinical Cancer Research
通讯作者	Lin,Wenchu(wenchu@hmfl.ac.cn)
摘要	An amendment to this paper has been published and can be accessed via the original article.
DOI	10.1186/s13046-020-01805-6
语种	英语
WOS记录号	BMC:10.1186/s13046-020-01805-6
出版者	BioMed Central
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/125702
专题	中国科学院合肥物质科学研究院
通讯作者	Lin,Wenchu
作者单位	1.Chinese Academy of Sciences; High Magnetic Field Laboratory 2.University of Science and Technology of China 3.Chinese Academy of Sciences; Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science
第一作者单位	中科院强磁场科学中心
通讯作者单位	中科院强磁场科学中心
推荐引用方式 GB/T 7714	Ma,Liying,Bian,Xing,Lin,Wenchu. Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer[J]. Journal of Experimental & Clinical Cancer Research,2021,40.
APA	Ma,Liying,Bian,Xing,&Lin,Wenchu.(2021).Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.Journal of Experimental & Clinical Cancer Research,40.
MLA	Ma,Liying,et al."Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer".Journal of Experimental & Clinical Cancer Research 40(2021).